Product Candidate	ASONEP™ (Systemic formulation of humanized Sphingomab™)	iSONEP™ (Ocular formulation of humanized Sphingomab™)	Lpathomab™	Nextomabs #1, #2, #3
Target	Sphingosine 1 Phosphate (S1P)	Sphingosine 1 Phosphate (S1P)	Lysophosphatidic Acid (LPA)	Other bioactive lipid targets
Primary Indications	Cancer, Inflammation	AMD, Diabetic Retinopathy, Glaucoma, Others	Cancer, Fibrosis, Neuropathic Pain	Inflammation, Cancer, Asthma, Sepsis, Others
Clinical Status	Phase 1 Partnered with Merck-Serono	Phase 1	Late Preclinical	Discovery